• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

连续处理制备脂质体制剂中关键工艺参数和关键物料属性对关键质量属性的影响。

Impact of critical process parameters and critical material attributes on the critical quality attributes of liposomal formulations prepared using continuous processing.

机构信息

Department of Pharmaceutical Sciences, UConn, Storrs, CT 06269, United States.

Department of Pharmaceutical Sciences, UConn, Storrs, CT 06269, United States.

出版信息

Int J Pharm. 2022 May 10;619:121700. doi: 10.1016/j.ijpharm.2022.121700. Epub 2022 Mar 28.

DOI:10.1016/j.ijpharm.2022.121700
PMID:35358645
Abstract

Liposomes were one of the earliest drug delivery vehicles used for anti-cancer therapeutics and similarly, lipid-based nanoparticles have been used for abundance of applications as gene therapies. The methods to produce these particles have remained relatively unchanged until the recent emergence of continuous manufacturing. Continuous processing enables accelerated development of nanoparticle formulations while providing a scalable manufacturing solution. For this work a continuous processing platform for the production of lipid and polymeric-based nanoparticle formulations has been developed at the University of Connecticut. This research focuses on the formation of liposomes encompassing multiple design of experiments (DoEs) to identify functional relationships between critical process parameters (CPPs), critical material attributes (CMAs), and critical quality attributes (CQAs) for liposomal formulations produced using this continuous processing platform. Liposomes of various sizes and of low polydispersity index (PDI) were produced with different material attributes under various processing conditions. In general, lower mole percentages of cholesterol produced larger particles whereas the mole percent of phosphatidylglycerol did not seem to have a s impact on the size of the liposomes that were produced. The results showed that similarly sized liposomes could be produced with different processing conditions allowing for the flexibility to operate in regions most suitable for formulation components that may be sensitive to certain processing conditions. For example, if the target size of a formulation is 100 nm but the active pharmaceutical ingredient is sensitive to temperature, then the formulation can be manufactured at high (55 °C) or low (30 °C) depending on its characteristics. Additionally, the relationships between CMAs and CPPs were different from conventional liposomal manufacturing methods, allowing for more flexibility when using a continuous processing system. Models that can effectively predict the hydrodynamic diameter of monodispersed liposomes produced using continuous processing were developed. The models developed from the DoEs in this study may be useful for accelerated development of new lipid formulations as well as facilitate the translation from traditional manufacturing methods to continuous manufacturing for products already on the market.

摘要

脂质体是最早用于抗癌治疗的药物输送载体之一,类似地,基于脂质的纳米粒子也被广泛应用于基因治疗等领域。直到最近连续制造技术的出现,这些粒子的生产方法才保持相对不变。连续处理能够加速纳米粒子配方的开发,同时提供可扩展的制造解决方案。为此,康涅狄格大学开发了一种用于生产脂质和聚合物纳米粒子配方的连续处理平台。本研究侧重于形成脂质体,涵盖了多项实验设计 (DoE),以确定使用这种连续处理平台生产的脂质体配方中关键工艺参数 (CPP)、关键材料属性 (CMA) 和关键质量属性 (CQA) 之间的功能关系。使用不同的材料属性在不同的处理条件下生产了各种大小和低多分散指数 (PDI) 的脂质体。一般来说,胆固醇的摩尔百分比越低,产生的颗粒越大,而磷脂酰甘油的摩尔百分比似乎对所产生的脂质体的大小没有影响。结果表明,在最适合可能对某些处理条件敏感的配方成分的区域中,可以使用不同的处理条件生产类似大小的脂质体,从而具有更大的灵活性。例如,如果配方的目标尺寸为 100nm,但活性药物成分对温度敏感,则可以根据其特性在高温(55°C)或低温(30°C)下制造配方。此外,CMA 和 CPP 之间的关系与传统的脂质体制造方法不同,这使得在使用连续处理系统时具有更大的灵活性。本研究中的 DoE 开发了能够有效预测使用连续处理生产的单分散脂质体水动力直径的模型。这些模型可能有助于加速新脂质配方的开发,并促进从传统制造方法向已上市产品的连续制造的转化。

相似文献

1
Impact of critical process parameters and critical material attributes on the critical quality attributes of liposomal formulations prepared using continuous processing.连续处理制备脂质体制剂中关键工艺参数和关键物料属性对关键质量属性的影响。
Int J Pharm. 2022 May 10;619:121700. doi: 10.1016/j.ijpharm.2022.121700. Epub 2022 Mar 28.
2
Artificial neural networks in tandem with molecular descriptors as predictive tools for continuous liposome manufacturing.人工神经网络与分子描述符相结合作为连续脂质体制造的预测工具。
Int J Pharm. 2021 Jun 15;603:120713. doi: 10.1016/j.ijpharm.2021.120713. Epub 2021 May 18.
3
Quality by design (QbD) optimization of diazepam-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery: Toxicological effect of surface charge on human neuronal cells.载有地西泮的纳米结构脂质载体(NLC)经鼻脑递药的质量源于设计(QbD)优化:表面电荷对人神经细胞的毒理学效应。
Int J Pharm. 2021 Sep 25;607:120933. doi: 10.1016/j.ijpharm.2021.120933. Epub 2021 Jul 27.
4
Quality by Design Approach in Liposomal Formulations: Robust Product Development.质量源于设计在脂质体制剂中的应用:稳健的产品开发。
Molecules. 2022 Dec 20;28(1):10. doi: 10.3390/molecules28010010.
5
Scalable microfluidic method for tunable liposomal production by a design of experiment approach.通过实验设计方法实现可扩展的脂质体生产的可扩展微流控方法。
Int J Pharm. 2024 Sep 5;662:124460. doi: 10.1016/j.ijpharm.2024.124460. Epub 2024 Jul 14.
6
Critical process parameters in manufacturing of liposomal formulations of amphotericin B.两性霉素 B 脂质体制剂生产中的关键工艺参数。
Int J Pharm. 2019 Jun 30;565:447-457. doi: 10.1016/j.ijpharm.2019.04.052. Epub 2019 May 6.
7
Managing API raw material variability in a continuous manufacturing line - Prediction of process robustness.在连续化制药生产线上管理原料药的变异性 - 预测工艺稳健性。
Int J Pharm. 2019 Oct 5;569:118525. doi: 10.1016/j.ijpharm.2019.118525. Epub 2019 Jul 15.
8
Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.局部脂质体中的他莫昔芬:研发、表征及体外评价
J Pharm Pharm Sci. 2004 Jul 16;7(2):252-9.
9
Continuous processing of paclitaxel polymeric micelles.紫杉醇聚合物胶束的连续处理。
Int J Pharm. 2021 Sep 25;607:120946. doi: 10.1016/j.ijpharm.2021.120946. Epub 2021 Jul 30.
10
Evaluation of size-based distribution of drug and excipient in amphotericin B liposomal formulation.评价两性霉素 B 脂质体制剂中药物和赋形剂的基于大小的分布。
Int J Pharm. 2019 Oct 5;569:118603. doi: 10.1016/j.ijpharm.2019.118603. Epub 2019 Aug 8.

引用本文的文献

1
Nanotechnological innovations in paediatric tuberculosis management: current trends and future prospects.儿科结核病管理中的纳米技术创新:当前趋势与未来前景
Front Drug Deliv. 2024 Jan 8;3:1295815. doi: 10.3389/fddev.2023.1295815. eCollection 2023.
2
Quality by Design and In Silico Approach in SNEDDS Development: A Comprehensive Formulation Framework.自乳化药物递送系统(SNEDDS)开发中的质量源于设计和计算机模拟方法:一个全面的制剂框架
Pharmaceutics. 2025 May 27;17(6):701. doi: 10.3390/pharmaceutics17060701.
3
Bridging membrane fluidity studies with a predictive model of drug encapsulation to address industrial challenges of liposomal injectables manufacturing.
将膜流动性研究与药物包封预测模型相结合,以应对脂质体注射剂生产中的工业挑战。
Drug Deliv Transl Res. 2025 Feb 15. doi: 10.1007/s13346-025-01807-x.
4
Lipid-based nanosystems: a pivotal solution in drug delivery.基于脂质的纳米系统:药物递送中的关键解决方案。
Nanomedicine (Lond). 2025 Jan;20(2):121-123. doi: 10.1080/17435889.2024.2426969. Epub 2024 Nov 14.
5
Process Robustness in Lipid Nanoparticle Production: A Comparison of Microfluidic and Turbulent Jet Mixing.脂质纳米粒生产中的过程稳健性:微流控与湍流射流混合的比较。
Mol Pharm. 2023 Aug 7;20(8):4285-4296. doi: 10.1021/acs.molpharmaceut.3c00390. Epub 2023 Jul 18.
6
Robotics and Aseptic Processing in View of Regulatory Requirements.基于监管要求的机器人技术与无菌处理
Pharmaceutics. 2023 May 24;15(6):1581. doi: 10.3390/pharmaceutics15061581.
7
Fabrication and Characterization of β-Cyclodextrin/ Essential Oil Inclusion Complexes: Experimental Design and Molecular Modeling.β-环糊精/精油包合物的制备与表征:实验设计与分子模拟。
Molecules. 2022 Dec 21;28(1):37. doi: 10.3390/molecules28010037.